Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging (fMRI) Study With Paroxetine Treatment
- Conditions
- Anxiety DisorderObsessive-Compulsive Disorder
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - Diagnostic criteria for GAD?PD?SAD?OCD patients according to the Structural Clinical<br> Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition<br> (DSM-V)<br><br> - Never received any treatment before,and with no psychotic symptoms<br><br> - For Healthy controls:Their ?rst-degree relatives had no history of psychiatric<br> disorders<br><br>Exclusion Criteria:<br><br> - Exclusion criteria for all participants were any other psychiatric diagnoses<br> according to DSM-V; any physical illness such as liver and kidney diseases,<br> cardiovascular diseases; any combined with other antipsychotic medications (both low<br> and high doses), including typical and atypical antipsychotic,mood stabilizer,<br> antidepressant drugs ; history of drug or alcohol abuse or dependence; obvious<br> suicide attempts or behaviors; pregnancy or lactation. and any contraindications to<br> MRI scan.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method structural and function MRI data;Hamilton anxiety scale(HAMA);Yale-Brown Obsessive Compulsive Scale(Y-BOCS);Brief Cognitive Assessment Tool for Schizophrenia (B-CATS)
- Secondary Outcome Measures
Name Time Method Social Disability Screening Schedule(SDSS);Simplified Coping Style Questionnaire (SCSQ);Eysenck Personality Questionnaire(EPQ);The 17-item Hamilton depression scale (HAMD-17);Liebowitz social anxiety scale(LSAS)